SPONSORED CONTENT: Scaling programs from clinical trials to commercialization requires more than raw capacity — it demands supply chain redundancy and rigid quality systems, notes Kerrie Powell from Alcami.

The simultaneous adoption of eCTD v4.0 and GxP-compliant AI tools offers the biopharma industry potentially tremendous efficiency gains; however, success will ultimately depend upon organizational agility.

Long-term value creation in bio/pharma now hinges on embedding environmental targets into early-phase development, according to Russell Miller from Enzene.

Scaling point-of-care and modular manufacturing requires companies to move beyond traditional paper-based reviews and into real-time digital execution with embedded quality control.

Once limited by poor bioavailability and enzymatic degradation, oral peptides are now on the cusp of becoming the next blockbuster class, reveal Hong Li and Lixia Zhang from BioDuro.

The shift from high-volume drugs to niche biologics requires a more than just expanded footprints, it demands smarter bioprocess controls, lower COGs early on in development, and cross-functional teams.

Driven by the rise of primary-care biologics and value-based healthcare, oral peptides and proteins are challenging traditional injectable paradigms, reveals Giuseppe De Franza from Adare Pharma Solutions.

According to Britton Jimenez, from Codexis, the future of RNA therapeutics lies beyond traditional synthesis and requires a shift in manufacturing strategy toward advanced and agile platforms and sourcing.

SPONSORED CONTENT: The IMA Active Competence Center Academy is a comprehensive e-learning platform that helps pharmaceutical manufacturers build expertise in solid dose production.

As poor solubility continues to plague development pipelines, alternative biocompatible permeation enhancers are becoming increasingly beneficial for formulation scientists notes Roger Viney from ICE Pharma.

Recent AI-related news is signaling a shift in the bio/pharma industry’s digital transformation from speculative molecule generation toward grounded biological context and downstream manufacturing execution.

Macroeconomic headwinds, compressed regulatory pathways, and an influx of asset-light virtual innovators are leading to an evolution in outsourcing service delivery models.

A novel pan-sarbecovirus vaccine candidate developed by the University of Cambridge and DIOSynVax has demonstrated safety in a Phase I, needle-free clinical trial.

SPONSORED CONTENT: Pedro Fernandes Botas and Mark Macdonald from Codis break down how advanced spray drying capabilities, mathematical modeling, and commercial operations experience are helping sponsors navigate the modern formulation landscape.

As specialized modalities push classical manufacturing models to their limits, organizations must treat internal talent development with the same level of process excellence they apply to biological pipelines.

Industry leaders are set to gather in Philadelphia to address fluctuating policy shifts, supply chain risks, and accelerating biologics investment across the global industry.

As bio/pharmaceutical drug development progresses and more complex molecules enter the pipeline, increased innovation and a rethink of excipient portfolios is necessary.

Marking Clinical Trial Awareness Day, Treehill Partners’ CEO Ali Pashazadeh details the flaws in clinical study designs and explains how high-velocity competition from Eastern markets is forcing a long-overdue industry redesign.

SPONSORED CONTENT: Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a need for simpler platform approaches, according to Kenneth Holbourn from FUJIFILM Biotechnologies.

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.